Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for use in two new indications, making it the only new oral anticoagulant approved in three indications across all 27 EU member states.
Xarelto is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, or AF, with one or more risk factors and for treatment of deep vein thrombosis, or DVT, and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults. It is also approved for prevention of Venous Thromboembolism, or VTE, in adult patients undergoing elective hip or knee replacement surgery.
by RTT Staff Writer
For comments and feedback: email@example.com